Loqtorzi®
LOQTORZI® (toripalimab-tpzi) is a PD-1 inhibitor used for the treatment of advanced nasopharyngeal carcinoma (NPC). Loqtorzi is a next-generation, programmed death receptor-1 (PD-1) monoclonal antibody that blocks PD-L1 and PD-L2, which allows the immune system to activate and kill the tumor. Loqtorzi works by blocking the PD-1 receptor on tumor cells so the immune system is more able to attack and kill tumor cells.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
MANUFACTURER: Coherus BioSciences, Inc. |
CLASS: Anti-PD-1 and PD-L1 Monoclonal Antibodies |
WHAT IT TREATS: Advanced Nasopharyngeal Carcinoma |
PRESCRIBED BY: Oncologists, Otorhinolaryngologists, Endocrinologists, Radiation oncologists, Medical oncologists, Oral/maxillofacial surgeons, and Maxillofacial prosthodontists
|
HOW ADMINISTERED: Intravenous Infusion |
FREQUENCY: Every two-three weeks |
Length of infusion: 60 mins |
